PUBLISHER: The Business Research Company | PRODUCT CODE: 1989270
PUBLISHER: The Business Research Company | PRODUCT CODE: 1989270
Regulatory affairs outsourcing involves external services utilized by pharmaceutical, biotech, and medical device manufacturing companies to expedite regulatory approvals from various organizations. These services encompass adherence to pharmaceutical regulations, quality standards, safety measures, efficacy criteria, and compliance with the attitudes and requirements of health authorities.
Regulatory affairs outsourcing services cover legal representation, regulatory consulting, product registration & clinical trial application, regulatory writing & publication, and others. Legal representation involves advocates handling legal work on behalf of pharmaceutical and medical device companies for regulatory approvals, covering medical devices, biologics, and drugs for various medical indications such as neurology, oncology, immunology, and cardiology. These outsourcing services are commonly adopted by companies in the medical device, biotechnology, and pharmaceutical sectors.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Tariffs indirectly affect the regulatory affairs outsourcing market by increasing operational costs of pharmaceutical, biotechnology, and medical device companies, which influences outsourcing dependency and spending priorities. Regions with large manufacturing and R&D hubs such as North America, Europe, and Asia-Pacific experience varying impacts depending on import dependencies and production shifts. Some regulatory service segments face increased documentation and compliance complexities due to tariff-driven trade policies. However, tariffs can also accelerate outsourcing demand as companies seek cost optimization and efficiency to manage regulatory burdens effectively.
The regulatory affairs outsourcing market research report is one of a series of new reports from The Business Research Company that provides regulatory affairs outsourcing market statistics, including regulatory affairs outsourcing industry global market size, regional shares, competitors with a regulatory affairs outsourcing market share, detailed regulatory affairs outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the regulatory affairs outsourcing industry. This regulatory affairs outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The regulatory affairs outsourcing market size has grown rapidly in recent years. It will grow from $9.43 billion in 2025 to $10.74 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to pharma r&d expansion, clinical research growth, regulatory complexity rise, globalization of trials, increasing approval timelines.
The regulatory affairs outsourcing market size is expected to see rapid growth in the next few years. It will grow to $18.29 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to biologics expansion, personalized medicine growth, increasing medical device innovation, rising compliance requirements, digital regulatory solutions adoption. Major trends in the forecast period include increasing outsourcing of compliance activities, rising demand for faster regulatory approvals, growing emphasis on clinical documentation services, increasing submission management outsourcing, rising complexity of global regulatory frameworks.
The increase in the number of clinical trials is expected to propel the growth of the regulatory affairs outsourcing market going forward. Clinical trials are scientific studies carried out with human participants to assess the safety, efficacy, and performance of new drugs, therapies, medical devices, or diagnostic methods. Regulatory affairs outsourcing is increasingly used in clinical trials as a strategic approach to manage and accelerate complex regulatory procedures in drug development. By leveraging external regulatory expertise, organizations can navigate evolving compliance requirements more effectively, ensure smooth communication with regulatory authorities, shorten development timelines, and enable faster market entry for new pharmaceutical products. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the number of pharmaceutical industry trials initiated in the UK rose for the second consecutive year, increasing from 411 in 2022 to 426 in 2023. Therefore, the rising number of clinical trials is driving the growth of the regulatory affairs outsourcing market.
Major players operating in the regulatory affairs outsourcing market are concentrating on developing innovative solutions such as regulatory affairs management software to improve compliance efficiency and optimize data handling. Regulatory affairs management software helps organizations centralize, monitor, and maintain regulatory submissions, approvals, and related documentation, reducing administrative workload while ensuring regulatory compliance. For example, in May 2024, Rimsys, a US-based software company, launched the beta version of its community-driven regulatory intelligence platform, Rimsys Intel. This free global regulatory intelligence hub is specifically designed for the medical technology sector and aims to improve access to critical regulatory information for the medtech community.
In December 2023, SGS, a Switzerland-based multinational corporation, formed a partnership with Agilex Biolabs. This collaboration aims to strengthen SGS's footprint in the Asia-Pacific region, leveraging its extensive network of bioanalytical laboratories, including a newly established facility in Shanghai. The partnership is designed to facilitate seamless operational integration, ensuring efficient transfer and validation of methods across different locations. Agilex Biolabs is an Australia-based regulated bioanalytical laboratory that provides substantial support for drug development programs across various sectors, including small molecules and biologics.
Major companies operating in the regulatory affairs outsourcing market report are Thermo Fisher Scientific Inc. (PPD), IQVIA, ICON plc, Parexel International Corporation, Syneos Health, WuXi AppTec, Charles River Laboratories International Inc., Medpace Holdings Inc., Certara L.P., PharmaLex GmbH, Promedica International, Clinilabs Inc., CliniExperts Pvt Ltd., Global Regulatory Services (GRS), Pharma Design Limited, BlueReg Group, Hiray Pharma Solutions, CTI Clinical Trial & Consulting Services, Accell Clinical Research LLC, Pace Life Sciences, Amicus GMP, MedReg Solutions
North America was the largest region in the regulatory affairs outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the regulatory affairs outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the regulatory affairs outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The regulatory affairs outsourcing market includes revenues earned by entities by providing services such as scope representation, full-service representation, ghostwriting representation, and fixed-rate representation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Regulatory Affairs Outsourcing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses regulatory affairs outsourcing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for regulatory affairs outsourcing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The regulatory affairs outsourcing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.